Wednesday, Mar 24, 2004
South San Francisco, Calif. -- March 24, 2004 --Genentech, Inc. (NYSE: DNA) today announced the promotion of Todd Pierce to vice president, Corporate Information Technology (CIT).
In this role, Pierce will continue to manage Genentech's CIT group, including information technology (IT) strategy, planning, application development, operations and networking. In addition, he will chair the company's IT Strategy Council. Pierce reports to Louis J. Lavigne, Jr., executive vice president and chief financial officer.
"Since joining Genentech, Todd has made significant contributions to our CIT organization, and he brings a tremendous amount of experience to this new position," said Lavigne. "I am confident that with Todd's expertise and leadership, our CIT organization is well-positioned to meet Genentech's information technology needs, both in the near term and going forward."
Pierce joined Genentech in May 2002 as senior director, CIT Operations, and was promoted to the head of CIT in October 2002. While at Genentech, Pierce established a clear blueprint for CIT's mission, strategies, projects, and communication channels. He has also enhanced the company's IT systems by upgrading its corporate-wide email system; improving customer communications at the management, desktop and call-center levels; and implementing a cellular data service network on all Genentech campuses. In addition, he helped form the IT Strategy Council, a cross-functional team of senior executives who coordinate and set direction for all of the company's IT activities.
Prior to joining Genentech, Pierce was chief information officer and director of information systems for the Santa Clara County Social Services Agency. He has more than 15 years of IT leadership experience from a broad range of industries, including commercial software products, health insurance, clinical care and government.
Pierce holds a Bachelor of Arts in Economics and Finance from Austin College and a Master of Arts in Health Policy and Administration from the University of California, Berkeley.
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Eighteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 13 biotechnology products in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.